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Decreased Striatal Monoaminergic Terminals
in Multiple System Atrophy Detected with
Positron Emission Tomography
Sid Gilman, MD,* Robert A. Koeppe, PhD,† Larry Junck, MD,* Roderick Little, PhD,‡ Karen J. Kluin, MS,*§
Mary Heumann, BS,* Susan Martorello, MS,* and Jewel Johanns, MS‡
We examined the density of striatal presynaptic monoaminergic terminals, using a ligand for the type 2 vesicular mono-
amine transporter, (1)-[11C]dihydrotetrabenazine, with positron emission tomography in 7 normal control subjects, 8
multiple system atrophy (MSA) patients with predominantly parkinsonian features (MSA-P), 8 MSA patients with prin-
cipally cerebellar dysfunction (MSA-C), and 6 sporadic olivopontocerebellar atrophy (sOPCA) patients. The findings
were correlated with the results of neurological evaluations and magnetic resonance imaging studies. Specific binding was
significantly reduced in the putamen of all patient groups in the order MSA-P < MSA-C < sOPCA, compared with
controls. Mean blood-to-brain ligand transport (K1) was significantly decreased in the putamen of all patient groups and
in the cerebellar hemispheres of MSA-C and sOPCA but not MSA-P groups, compared with controls. Significant negative
correlations were found between striatal binding and the intensity of parkinsonian features and between cerebellar K1
and the intensity of cerebellar dysfunction. The results suggest fundamental differences between MSA-P and MSA-C
groups reflecting differential severity of degeneration of nigrostriatal and cerebellar systems in these two forms of MSA.
The findings also show that some sOPCA patients have subclinical nigrostriatal dysfunction and are at risk of developing
MSA with disease progression.
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Multiple system atrophy (MSA) is a sporadic neurode-
generative disease of undetermined cause characterized
by combinations of the parkinsonian symptoms of bra-
dykinesia and rigidity that are poorly responsive or un-
responsive to levodopa (ie, cerebellar ataxia, and auto-
nomic insufficiency, frequently accompanied by signs
of corticospinal tract disease).1–10 Some MSA patients
initially develop a parkinsonian syndrome (MSA-P)
followed by autonomic dysfunction or cerebellar man-
ifestations or both. In others, MSA begins with cere-
bellar manifestations (MSA-C) followed by autonomic
dysfunction or parkinsonian features or both. MSA is a
distinct entity clinically, neuropathologically, and bio-
chemically.1–4,11–20 The neuropathological findings
consist principally of neuronal loss and gliosis in the
caudate nucleus, putamen, external pallidum, substan-
tia nigra, locus ceruleus, inferior olives, pontine nuclei,
cerebellar Purkinje cells, and intermediolateral cell col-
umns of the spinal cord.21–25 Other structures showing
variable involvement include the thalamus, vestibular
nucleus, dorsal vagal nucleus, corticospinal tracts, and
anterior horn cells.4,21–25 Oligodendroglial26–30 and
neuronal31–34 intracytoplasmic and intranuclear inclu-
sions are characteristic of MSA and are widely distrib-
uted in the central nervous system.
Sporadic olivopontocerebellar atrophy (sOPCA), also
termed idiopathic sporadic cerebellar ataxia or idio-
pathic late-onset cerebellar ataxia, is a neurodegenera-
tive disease of undetermined cause.35–41 The symp-
toms consist of progressive ataxia of gait, speech, and
limb movements accompanied by disturbances of ex-
traocular movements and, in some patients, signs of
corticospinal tract disease.35–39 The neuropathological
changes usually consist of neuronal loss and gliosis in
the brainstem (inferior olives, pontine nuclei, and ves-
tibular nuclei) and cerebellum (molecular, Purkinje
cell, and granular layers).22,40–42 Some patients who
initially present with sOPCA later develop autonomic
failure and parkinsonian features, indicating progres-
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sion to MSA, and at post mortem they show neuro-
pathological changes typical of MSA.1–4
At present, no method is available to determine
whether individual sOPCA patients will progress to de-
velop MSA.12 The diagnosis of MSA carries a more
grave prognosis than sOPCA, hence a means of pre-
dicting the evolution of sOPCA into MSA would be
useful clinically. In addition, although MSA patients
clinically affected by parkinsonism, autonomic dys-
function, and cerebellar manifestations show at post
mortem degenerative changes in the brainstem, cerebel-
lum, nigrostriatal connections, and spinal cord, the de-
gree of involvement of these individual structures in
patients with principally cerebellar or parkinsonian fea-
tures is not known.
In a previous investigation, we used (6)-
[11C]dihydrotetrabenazine [(6)-[11C]DTBZ], a new li-
gand for the type 2 vesicular monoamine transporter
(VMAT2), with positron emission tomography (PET)
to examine the density of striatal monoaminergic pre-
synaptic terminals in MSA compared with sOPCA pa-
tients and normal controls.16 Mean ligand binding was
significantly decreased in the striatum of 4 MSA pa-
tients and marginally diminished in the striatum of 8
sOPCA patients compared with 9 normal controls.
These findings demonstrated severe nigrostriatal pa-
thology in MSA and suggested asymptomatic involve-
ment in the sOPCA group, indicating that some of the
sOPCA patients may later develop parkinsonian fea-
tures. The MSA group was too small to compare dif-
ferences in binding in the MSA-P compared with the
MSA-C patients studied.
We initiated the current investigation to examine a
larger cohort of MSA patients to determine whether
striatal monoaminergic presynaptic terminals are differ-
entially affected in MSA-P compared with MSA-C pa-
tients and to compare the findings in these two groups
with a group of sOPCA patients and a group of simi-
larly aged normal controls. Recently, our radiochemists
succeeded in separating the active (1) enantiomer
from the inactive (2) enantiomer of DTBZ. In this
study we used the (1) enantiomer of [11C]DTBZ, ef-
fectively doubling the VMAT2 signal previously ob-
tained with the (6) ligand.16 A preliminary version of
this study has been published in abstract form.43
Subjects and Methods
Patient Groups and Normal Subjects
The Institutional Review Board of the University of Michi-
gan approved this investigation. We obtained informed con-
sent from all participants. We studied 7 normal control sub-
jects (all men; age, 57 6 13 years; mean 6 SD), 8 patients
with MSA-P (6 men and 2 women; 65 6 10 years), 8 with
MSA-C (3 men and 5 women; 62 6 5 years), and 6 with
sOPCA (2 men and 4 women; 54 6 18 years) (Table 1).
The controls were selected to have age distributions similar
Table 1. Clinical Features in Patients with Multiple System Atrophy Presenting with Parkinsonian Features (MSA-P),
























Sex M F M M M M F M F M F
Age (yr) 44 67 84 67 81 66 56 63 64 59 54
Duration of symptoms (yr) 1.5 3 4 2.5 5 2 7 4 6 5 7
Akinesia 11 1 11 11 1 1 111 111 1 1 1
Rigidity 11 1 111 1 1 1 111 111 1 1 1
Parkinsonian gait 11 1 1 1 1 1 11 111 2 2 2
Tremor (extrapyramidal) 2 2 2 2 1 2 2 2 2 2 2
Hypokinetic speech 11 1 111 1 1 2 111 111 1 1 2
Response to levodopa 2 2 2 2 11 2 2 11 NA NA NA
Ocular dysmetria 1 2 2 2 2 2 2 2 1 2 1
Gait ataxia 1 2 2 11 2 2 2 2 111 11 111
Limb ataxia 1 2 1 1 2 2 2 1 111 11 111
Ataxic speech 1 2 1 11 2 1 11 2 11 11 111
Spastic speech 2 11 11 1 2 1 11 2 1 1 1
Extensor plantar signs 2 2 2 2 2 1 1 1 2 1 2
Postural hypotension 11 11 1 2 1 11 111 11 111 1 111
Urinary incontinence 111 111 1 2 2 2 11 11 111 11 11
(Stool 1)
MRI atrophy NA NA
Cerebral 2 2 2 2 1 2 2 2 2
Basal ganglia 2 2 2 2 1 11 2 2 2
Cerebellar 2 2 2 1 2 1 11 11 1
Brainstem 1 2 1 1 2 1 111 111 1
Scales: 2 5 none; 1 5 mild; 11 5 moderate; 111 5 marked; NA 5 not available; MRI 5 magnetic resonance imaging.
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to those of the patient groups. The controls had no history
of neurological disorders and no abnormalities on general
physical and neurological examinations. None of the patients
or controls were receiving centrally active medications that
could influence striatal VMAT2 binding.16,44
We classified the patients with MSA according to the pre-
senting feature (parkinsonism or cerebellar ataxia), and in
these patients the presenting feature was also the more severe
feature (see Table 1). The diagnosis of MSA-P was based on
the demonstration of a parkinsonian syndrome in combina-
tion with (1) autonomic failure in 5 patients and (2) auto-
nomic failure and cerebellar ataxia in 3. The diagnosis of
MSA-C was based on the finding of cerebellar ataxia with (1)
autonomic failure in 5 patients, (2) autonomic failure and
parkinsonism in 2, and (3) parkinsonism without autonomic
failure in 1. The diagnosis of a parkinsonian syndrome re-
quired at least two of the following: bradykinesia, rigidity,
tremor, or hypokinetic dysarthria, all poorly responsive or
unresponsive to levodopa. The diagnosis of cerebellar dys-
function required at least two of the following: gait ataxia,
limb ataxia, ataxic dysarthria, or sustained gaze-evoked nys-
tagmus, in the absence of other disorders that could cause
progressive ataxia such as sensory loss, medications, toxins,
cerebellar neoplasms, paraneoplastic cerebellar degeneration,
or multiple sclerosis. The diagnosis of autonomic failure re-
quired postural hypotension or urinary incontinence, the lat-
ter not caused by either outflow obstruction or abnormal
bladder suspension. Although all male patients studied had
erectile dysfunction, this was not included in the criteria be-
cause of the many possible causes of this symptom. The cri-
teria for postural hypotension were an orthostatic drop of 30
mm or more in systolic blood pressure and 20 mm or more
in diastolic blood pressure with an increase in heart rate of
no more than 10 beats per minute45 in the absence of med-
ication, dehydration, or medical disorders that might cause
this finding.46 We measured blood pressure and pulse with
the patient supine and again 2 to 3 minutes after the patient
had assumed a standing position.
We studied 6 patients with sOPCA. The diagnosis was
based on the finding of a sporadically occurring progressive
deterioration of cerebellar function manifested by at least two
of the following: gait ataxia, limb ataxia, ataxic dysarthria, or
sustained gaze-evoked nystagmus, in the absence of other dis-
orders that could cause progressive ataxia such as sensory
loss, medications, toxins, cerebellar neoplasms, paraneoplastic
cerebellar degeneration, or multiple sclerosis. To ensure that
the disorder was sporadic, we took a full family history, in-
cluding details concerning the parents, grandparents, aunts,
uncles, siblings, and children. The diagnosis of sOPCA was
assisted by finding cerebellar atrophy in magnetic resonance
(MR) scans in all 6 patients (see Table 1), although this find-
ing was not required as sOPCA can occur without demon-
strable atrophy in anatomical imaging studies.47
Patient Evaluations
We evaluated all patients with a detailed history, physical
examination, neurological examination, laboratory tests to
exclude other diseases, and MR imaging to exclude demyeli-
native disease and structural abnormalities. Speech was eval-
uated as described previously.48,49 We obtained a complete
blood count, serum profiles of hepatic and renal function, a
serological test for syphilis, serum levels of vitamins E, B12,























M F F M F F F M M F F
63 62 67 67 53 52 39 73 76 28 55
1.5 5 3 2 8 4 3 3 3 17 6
2 1 1 1 2 2 2 2 2 2 2
1 111 1 1 2 2 2 2 2 2 2
1 111 1 11 2 2 2 2 2 2 2
2 111 2 2 1 2 2 2 2 2 2
1 2 1 2 1 1 2 2 2 2 2
NA 1 NA NA NA NA 2 NA NA NA 2
1 1 1 1 11 1 1 1 11 11 111
11 11 1 11 11 111 11 11 11 11 111
1 1 2 11 11 1 11 1 1 111 11
11 11 1 11 111 11 11 1 2 1 11
2 1 2 2 1 1 NA 2 2 2 11
2 1 2 2 1 2 2 2 1 2 2
1 1 11 1 111 2 2 2 2 2 2
2 1 111 1 11 2 2 2 2 2 2
NA NA NA
2 2 2 2 2 2 2 2
2 2 2 2 2 2 2 2
1 1 11 111 111 111 111 1
11 1 11 1 1 1 1 11
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with symptoms for fewer than 3 years, we searched for an
occult malignancy with breast and pelvic examinations in
women, prostate examination in men, acid phosphatase and
prostate-specific antigen levels, anti-Purkinje cell antibodies
in blood samples, stool guaiac tests for occult blood, and
chest x-rays. The neurological examinations were conducted
by a neurologist (S.G.) and the speech evaluations by a
speech pathologist (K.J.K.), both of whom were blinded to
the PET data. Based on the examinations, the parkinsonian
and cerebellar features were graded on a scale of 2 5 none,
1 5 mild, 11 5 moderate, and 111 5 severe (see Table
1). The autonomic features were graded on the same scale
based on the history (for urinary incontinence) and the ex-
amination (for postural hypotension).
Magnetic Resonance Imaging
Full sets of MR scans were available to review for 17 of the
22 patients studied. The pulse sequence varied among scans,
but essentially all included inversion-recovery sequences with
T1-weighted, T2-weighted, and proton-density images. One
of the authors (L.J.) who was blinded to patient diagnoses
reviewed these scans. He evaluated the severity of atrophy in
the cerebral cortex, basal ganglia, cerebellum, and brainstem
(mesencephalon, pons, and medulla), using perceptual anal-
ysis, taking into account patient ages. The degree of atrophy
was graded on a scale of 2 5 none, 1 5 mild, 11 5 mod-
erate, and 111 5 severe (see Table 1). The results of the
evaluations of MR scans were not used for quantitative study.
Positron Emission Tomography Studies
The ligand (1)-[11C]DTBZ binds to the VMAT2 site, and
this site is not regulated by the effects of diseases or medi-
cations, including levodopa and numerous other pharmaceu-
ticals.16,44 Hence medications need not be stopped before
PET scanning, and in this study none of the medications
taken by the patients or normal controls were discontinued.
The subjects were placed on a table where they lay quietly
through the scanning procedure, eyes open, ears unoccluded,
alert but not speaking. We inserted a catheter in a radial
artery for blood sampling and placed radioactive fiducial
markers on the scalp to register the dynamic sequence of
frames, correcting for motion between frames of the study.
We imaged the subjects with a CTI PET Systems (Knoxville,
TN) ECAT EXACT-47 PET scanner, which has an intrinsic
in-plane resolution of 6.0-mm full-width at half-maximum
(FWHM) at the center of the field of view and an axial res-
olution of 5.0-mm FWHM. The reconstructed resolution
was approximately 9.0-mm FWHM. Forty-seven planes with
a 3.375-mm center-to-center separation were imaged simul-
taneously. Attenuation correction was calculated by the stan-
dard ellipse method.
We prepared (1)-[11C]DTBZ by 11C-methylation of
a-(1)-9-O-desmethyl-DTBZ, with a solid phase–supported
system allowing purification and isolation of the product
(1)-[11C]DTBZ without high-performance liquid chroma-
tography purification. We administered intravenously 18 6
1 mCi of (1)-[11C]DTBZ containing less than 50 mg of
mass of DTBZ. Arterial blood samples were collected every
10 seconds for 2 minutes, then at 2.5, 3, 4, 5, 7.5, 10, 15,
20, 30, 45, and 60 minutes after injection. Samples at 1, 2,
and 3 minutes and all subsequent samples were analyzed for
radiolabeled metabolites by using C-18 SEP-PAK chroma-
tography as described previously.44 We recorded a sequence
of 15 scans over 60 minutes from the time of injection.
Pharmacokinetic Analysis
We performed pixel-by-pixel fits to a two-compartment
tracer kinetic model, using a weighted integration method.
The analysis provided parametric images of total tissue dis-
tribution volume (DV) of DTBZ relative to authentic
DTBZ in arterial plasma50 and parametric images of ligand
transfer from plasma to brain (K1), which are highly corre-
lated with flow because the single-pass extraction fraction is
greater than 50%.
Volumes of Interest Analysis
For measurements from the caudate nucleus and putamen,
we created anatomically configured volumes of interest
(VOIs) from parametric images of DV, then placed these
VOIs on K1 images. For measurements from the cerebellar
hemispheres, we created anatomically configured VOIs from
parametric images of K1, then placed these VOIs on DV
images. VOIs were acquired from the two adjacent axial lev-
els that contained the peak parameter values (K1 or DV) of
each of the three structures (caudate nucleus, putamen, and
cerebellar hemispheres). VOIs for these three structures were
0.6, 1.1, and 1.7 ml, respectively. As a comparison, with the
PET scanner used, the volume of a resolution element is ap-
proximately 0.6 ml. For normalization of data obtained from
subcortical structures, VOIs were obtained from the cerebral
cortex in 8 to 10 adjacent horizontal slices extending from
the lowest slice containing the thalamus up to the first slice
in which the cortex could be seen along the entire medial
surface, which is above the level of the corpus callosum and
ventricles. The cerebral cortex contains few specific binding
sites, making it an appropriate region for normalization. We
subtracted the cortical DV from the total DV of each VOI
before normalization [(DVVOI 2 DVctx)/DVctx] to remove
free and nonspecifically bound tracer and thereby obtain a
measure of normalized specific binding, commonly termed
binding potential (BP). Note that BP is simply DVVOI nor-
malized to cortex minus 1.
Data Analysis
We compared mean BP and K1 values in the diagnostic
groups (MSA-P, MSA-C, sOPCA, and normal controls) by
analysis of covariance (ANCOVA), adjusting for age and sex,
for each of three anatomical sites (caudate nucleus, putamen,
and cerebellar hemispheres). As the groups had similar al-
though not identical mean ages, age adjustment had a small
effect in the ANCOVA. Pairwise group comparisons were
conducted using t tests, and p values are presented without
corrections for multiple comparisons. Within-group vari-
ances were treated as constant in BP analyses, but allowed to
differ between groups in K1 analyses to reflect the inequality
of variances observed. We normalized to the whole brain
cortex, and made no corrections for the effects of tissue at-
rophy. We examined the relation between symptom intensity
of the parkinsonian features and VMAT2 binding in the
caudate nucleus and putamen and between symptom inten-
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sity of the cerebellar dysfunction and K1 values in the cere-
bellum. Regression models were used to obtain correlations
for the above relations on all three patient groups. Pearson
correlations were computed on age-adjusted values derived




For the three patient groups compared with the control
group, mean BP values adjusted for age and sex were
reduced in the caudate nucleus and putamen in the
order MSA-P , MSA-C , sOPCA (Table 2).
ANCOVA revealed highly significant differences be-
tween groups for the caudate nucleus and putamen,
but no differences for the cerebellar hemispheres. Com-
parison of MSA-P patients with controls showed a
59% lower adjusted mean BP in the caudate nucleus
(p , 0.0001) and a 71% lower adjusted mean in the
putamen (p , 0.0001). For MSA-C patients com-
pared with controls, corresponding reductions were
43% in the caudate nucleus (p 5 0.002) and 55% in
the putamen (p , 0.0001). Adjusted means for
MSA-P and MSA-C groups did not differ significantly,
but the MSA-P subjects had 27% lower BP in the cau-
date nucleus and 35% lower BP in the putamen than
the MSA-C subjects. For sOPCA patients, adjusted
means were intermediate between those of control and
MSA groups in both the caudate nucleus and putamen.
Adjusted means for both regions were significantly lower
for both MSA groups than for the sOPCA group (p ,
0.05). Comparison of sOPCA patients with controls
showed a statistically significant difference in the puta-
men (p 5 0.04) but not in the caudate nucleus (p 5
0.25).
[11C]D ihydrotetrabenazine Transport (K1)
ANCOVA revealed significant differences between
groups for all three regions (see Table 2). Pairwise
group comparisons of MSA-P patients with controls
showed a nonsignificant 7% decrease of adjusted mean
K1 in the caudate nucleus and a significant (p 5 0.04)
12% decrease in the putamen. For MSA-C patients,
adjusted mean K1 values in the caudate nucleus and
putamen were the lowest of the four groups, and were
significantly different from both normal controls and
sOPCA patients (p , 0.05). Adjusted means of the
MSA-C group were decreased 12% in the caudate nu-
cleus and 16% in the putamen compared with con-
trols. Adjusted means of the MSA-C group were de-
creased 8% in the caudate nucleus and 8% in the
putamen compared with the sOPCA group (p , 0.05,
for each structure). The MSA-P and MSA-C groups
did not differ significantly in adjusted means for the
caudate nucleus and putamen. For sOPCA patients,
adjusted means in the caudate nucleus and putamen
were intermediate between those of the controls and
MSA patients. Comparison of sOPCA patients with
controls revealed no significant change in the caudate
nucleus and a 8% reduction in the putamen (p 5
0.03). In the cerebellar hemispheres, the adjusted mean
values for MSA-P patients were the highest of the pa-
tient groups and not significantly different from the
control group, the values for MSA-C were the lowest,
and the sOPCA group fell between the two MSA
groups. Pairwise group comparisons with controls
showed a 48% decrease in the adjusted mean for
MSA-C patients (p , 0.0001) and a 22% decrease for
sOPCA patients (p 5 0.03). The adjusted mean for
Table 2. Comparison of PET Measurements of (1) -[11C ]Dihydrotetrabenazine Binding Potential (BP) and Normalized Ligand
Transport (K1) in Normal Controls and Patients with Multiple System Atrophy Showing Predominantly Parkinsonian Features










(n 5 6) pa
BP
Caudate nucleus 2.68 6 0.25 1.11 6 0.20b 1.52 6 0.19b 2.28 6 0.22c,d ,0.0001
Putamen 2.92 6 0.24 0.85 6 0.19b 1.30 6 0.19b 2.22 6 0.22b–d ,0.0001
Cerebellar hemispheres 0.27 6 0.05 0.26 6 0.04 0.24 6 0.04 0.13 6 0.04 0.125
K1 (normalized)
Caudate nucleus 1.16 6 0.03 1.08 6 0.07 1.02 6 0.03b 1.11 6 0.02d 0.019
Putamen 1.28 6 0.03 1.13 6 0.06a 1.08 6 0.02b 1.18 6 0.03b,d 0.0003
Cerebellar hemispheres 1.19 6 0.04 1.08 6 0.08 0.62 6 0.04b,c 0.93 6 0.10b,d ,0.0001
Data are mean 6 SE values, adjusted for age and sex. Whole brain cortex was used for both calculating BP and normalizing K1.
aFrom analysis of covariance model F test of equivalent means in the four groups adjusted for age and sex. Weighted least-squares analysis used
for all K1 variables to adjust for unequal variances of the groups.
bStatistically significant difference from controls at level 0.05.
cStatistically significant difference from MSA-P at level 0.05.
dStatistically significant difference from MSA-C at level 0.05.
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the cerebellum in MSA-C patients was 43% lower than
in MSA-P patients (p , 0.0001).
Magnetic Resonance Imaging
The MR scans revealed mild atrophy of the cerebral
cortex in 3 of the 8 MSA-P patients, 1 of the 8
MSA-C patients, and none of the sOPCA group (see
Table 1). The basal ganglia showed mild to moderate
atrophy in 2 MSA-P patients and no atrophy in any of
the other patients. In the cerebellum, atrophy was mild
to moderate in 4 of the 8 MSA-P patients, mild to
moderate in 7 of the 8 MSA-C patients, and mild to
severe in all 6 sOPCA patients. In the brainstem, atro-
phy was mild to severe in 5 of the 8 MSA-P patients,
mild to severe in all 8 MSA-C patients, and mild to
moderate in 5 of the 6 sOPCA patients.
Relation of Neurological Dysfunction to BP and K1
The autonomic dysfunction was approximately equal
in severity in the MSA-P compared with the MSA-C
groups (Table 3). As expected from the clinical classi-
fications of these patients, the parkinsonian signs were
much more severe in MSA-P than in MSA-C patients,
and the cerebellar dysfunction was much worse in
MSA-C than in MSA-P patients (see Table 3). The
severity of cerebellar dysfunction was approximately
equal in MSA-C compared with sOPCA patients.
Analysis of the three patient groups together revealed a
strong negative correlation between the intensity of the
parkinsonian features and BP in the caudate nucleus
(r 5 20.62, p 5 0.002) and putamen (r 5 20.61,
p 5 0.002). For example, a one-unit increase (for ex-
ample, from 1 to 11) in all five components of the
scale yielded a 20% decrease in mean caudate nucleus
and putamen BP. Analysis of the three patient groups
together also revealed a negative correlation between
the intensity of the cerebellar dysfunction and cerebel-
lar K1 (r 5 20.50, p 5 0.017). A one-unit change in
each of the four clinical measures of cerebellar function
resulted in a 16% decrease in K1.
Discussion
We found significantly decreased specific binding of
(1)-[11C]DTBZ to striatal monoaminergic presynaptic
terminals in the caudate nucleus and putamen in
MSA-P and MSA-C patients compared with normal
controls. Specific binding was not significantly differ-
ent between the two patient groups, but the MSA-P
subjects had substantially lower BPs in the caudate nu-
cleus and putamen than the MSA-C subjects. We also
found a strong negative correlation between the inten-
sity of the parkinsonian features and binding in the
caudate nucleus and putamen in all patient groups
combined. The present study augments our previous
investigation of striatal monoaminergic presynaptic
terminals utilizing (6)-[11C]DTBZ in MSA and
sOPCA.16 In that study we found in MSA, compared
with controls, significantly reduced BP in the caudate
nucleus and putamen, but the patient group was insuf-
ficient in size to differentiate changes in MSA-P and
MSA-C patients.
A recent study51 using (1)-[11C]DTBZ to compare
striatal monoaminergic presynaptic binding in Parkin-
son’s disease with normal controls revealed declines in
BP of 66% (in the anterior putamen) to 74% (in the
posterior putamen) in the Parkinson’s disease group.
These values are close to the declines in BP of 71% in
the putamen in MSA-P and 59% in MSA-C patients
in the present investigation. The similar level of decline
of BP in the putamen in Parkinson’s disease and
MSA-P patients suggests that the parkinsonian features
of both disorders result predominantly from deficiency
of the nigrostriatal projections. The lesser decline of BP
in the MSA-C than the MSA-P patients may explain
the less intense parkinsonian features of the MSA-C
patients. In addition, the prominent cerebellar degen-
eration in MSA-C patients may mitigate to some ex-
tent the clinical expression of parkinsonism. The hypo-
tonia typical of cerebellar disease52 may counteract the
rigidity that usually results from loss of nigrostriatal
terminals.
In two previous investigations, [18F]fluorodopa was
used with PET to study striatal monoaminergic presyn-
aptic terminals in MSA. One study included 10 MSA
patients, all of whom had a parkinsonian syndrome
with autonomic failure, and 7 of the 10 also had cer-
ebellar ataxia.53 Mean ligand uptake was reduced in the
caudate nucleus by 46% and in the putamen by 62%
in comparison to the normal controls. In our MSA-P
patients, who are clinically similar to the patients in
this study, mean ligand binding was reduced in the
caudate nucleus by 59% and in the putamen by 71%
Table 3. Severity of Autonomic, Cerebellar, and Parkinsonian










50.0 6 33.3 58.3 6 32.1 0.0 6 0.0
Cerebellar
manifestations
15.6 6 15.1 57.3 6 18.1 58.3 6 15.8
Parkinsonian signs 47.5 6 22.4 25.0 6 18.8 1.1 6 2.7
Data are mean 6 SD values. Scores for autonomic dysfunction
are based on two measures; hence, the maximum score (two
measures with three levels of severity) is 6; cerebellar manifesta-
tions are based on four measures; hence, the maximum score is
12; scores for parkinsonian signs are based on 5 measures;
hence, the maximum score is 15. The scores were transformed
to a uniform scale by dividing the individual scores by the max-
imum value for that score and multiplying by 100.
MSA-P 5 multiple system atrophy with parkinsonian features;
MSA-C 5 MSA with cerebellar features; sOPCA 5 sporadic
olivopontocerebellar atrophy.
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in comparison with the normal controls. A second
study also contained 10 patients, but all were described
as having OPCA with autonomic failure.15 Mean li-
gand uptake was reduced by 11% in the caudate nu-
cleus and 29% in the putamen compared with the con-
trols. In our MSA-C patients, who are similar to the
patients in this study, mean ligand binding was de-
creased by 43% in the caudate nucleus and 55% in the
putamen. Hence, our study demonstrated greater re-
ductions of binding in striatal monoaminergic presyn-
aptic terminals than either of the previous investiga-
tions. This may be because VMAT2 is decreased in
direct proportion to loss of nigrostriatal terminals,
whereas compensatory up-regulation occurs in some of
the processes responsible for [18F]fluorodopa uptake,
which include transporter and dopa decarboxylase ac-
tivity. An alternate explanation is that the disorder in
the patients we studied may be more advanced than
those in the other studies.
In the sOPCA group compared with the normal
controls, specific binding of (1)-[11C]DTBZ was de-
creased in the caudate nucleus and putamen, and the
difference reached statistical significance in the puta-
men. These findings supplement our previous study,
which showed decreased binding in both the caudate
nucleus and putamen, but the change was marginally
significant in the caudate nucleus and nonsignificant in
the putamen.16 The results of both studies suggest that
at least some of the sOPCA patients examined are de-
veloping nigrostriatal pathology and in the future may
exhibit symptoms of parkinsonism.
In the current study, mean blood-to-brain transport
(K1) of (1)-[
11C]DTBZ was significantly decreased in
the putamen of all patient groups compared with nor-
mal controls, with a slightly greater but nonsignificant
decrease in the MSA-C compared with the MSA-P
group, and with the least change in the sOPCA group.
The finding of significantly decreased K1 values in the
patient groups reflects diminished cerebral blood flow,
most likely from decreased metabolic and perfusion de-
mands caused by loss of nigrostriatal terminals. This is
in keeping with our earlier finding of decreased striatal
glucose metabolism in MSA and sOPCA.12 K1 values
in the caudate nucleus and putamen were significantly
lower in MSA-C than sOPCA patients, reflecting the
more severe striatal degeneration in the MSA-C group.
We found significantly decreased K1 values in the
cerebellar hemispheres of MSA-C and sOPCA groups
compared with controls. This finding indicates that
cerebellar blood flow is decreased in these groups,
probably from decreased metabolic and perfusion de-
mands. In the MR scans, cerebellar atrophy varying
from mild to severe was found in almost all MSA-C
and sOPCA patients, supporting the notion that tissue
atrophy is an important factor in the decreased perfu-
sion. In contrast to the other two patient groups, the
MSA-P subjects showed no significant difference from
controls in cerebellar K1 values, suggesting that cere-
bellar blood flow was, at most, minimally decreased. In
accord with this, only mild cerebellar dysfunction was
found on clinical examination in this group and only 2
patients had MR evidence of cerebellar atrophy, mild
in both cases.
In the present study, we defined VOIs by using the
peak site of [11C]DTBZ binding in the striatum visu-
alized in the PET images. The excellent signal obtained
in these images is partly the result of high levels of
binding in the striatum and low levels in the surround-
ing structures. This method provides a more reliable
means of extracting binding information from the
structures of interest than anatomical imaging with
MR imaging scans. MR imaging might be helpful in
delineating the exact boundaries of structures, but
would provide no greater accuracy in assessing binding.
Partial volume effects in this study may have influ-
enced the ligand binding data to some extent. As the
sizes of the structures, particularly the caudate nucleus,
and the VOIs used are moderately small relative to the
resolution of the reconstructed scans, partial volume ef-
fects would influence data from both patients and con-
trol subjects. It is highly unlikely, however, that the
binding estimates could reflect only atrophic changes
in the striatum of the patient groups for several rea-
sons. First, only 2 patients had noticeable atrophy in
the basal ganglia. With minimal atrophy, partial vol-
ume effects should be similar in patients and controls.
The observed decreases in VMAT2 binding in MSA-P
and MSA-C patients were 59% and 43% in the cau-
date nucleus and 71% and 55% in the putamen, re-
spectively. These decreases far exceed the changes that
could be attributed to differences in partial volume ef-
fects between patients and controls. Second, the strat-
egy of centering VOIs on the peak binding within the
caudate nucleus and putamen reduces partial volume
effects. Third, even if slight atrophy in the MSA pa-
tients caused greater partial volume effects in patients
than controls and this atrophy slightly affected the
PET measurements, this would not invalidate the con-
clusion that DTBZ binding is decreased and nigrostri-
atal terminals are lost in MSA. If the putamen were
atrophied without loss of nigrostriatal terminals, mea-
sured binding would be increased. Even in the presence
of atrophy, decreased VOI values lead to the conclu-
sion that DTBZ binding to nigrostriatal terminals is
decreased in MSA. With respect to the cerebellum, the
decreases in K1 in the MSA-C and sOPCA groups may
be influenced by partial volume effects to a greater ex-
tent than the basal ganglia. Atrophy results not only
from global cerebellar shrinkage, however, but also from
shrinkage between folia. MR imaging–based correction
for atrophy in the cerebellum may be helpful in correct-
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ing for effects from global shrinkage, but would not be
helpful for the effects of atrophy between the folia.
Taken together, the data presented suggest fun-
damental differences between MSA-P and MSA-C
groups. Degeneration of striatal monoaminergic pre-
synaptic terminals is greater in MSA-P than MSA-C
patients, as indicated by both lower specific binding in
the caudate nucleus and putamen and more intense
parkinsonian signs. In contrast, degeneration of cere-
bellar tissue is greater in MSA-C than MSA-P patients,
as shown by lower K1 values, greater atrophy in MR
scans, and more severe signs of cerebellar deficiency.
These differences may reflect differential severity of de-
generation of nigrostriatal and cerebellar systems in
these two forms of MSA, with either relative preserva-
tion or slower degenerative changes of the cerebellum
in MSA-P and the striatum in MSA-P.
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